Abstract

BackgroundGastroenteropancreatic neuroendocrine tumors most commonly metastasize to the liver; however, high normal background 68Ga-DOTATATE activity and high image noise make metastatic lesions difficult to detect. The purpose of this study is to develop a rapid, automated and highly specific method to identify 68Ga-DOTATATE PET/CT hepatic lesions using a 2D U-Net convolutional neural network.MethodsA retrospective study of 68Ga-DOTATATE PET/CT patient studies (n = 125; 57 with 68Ga-DOTATATE hepatic lesions and 68 without) was evaluated. The dataset was randomly divided into 75 studies for the training set (36 abnormal, 39 normal), 25 for the validation set (11 abnormal, 14 normal) and 25 for the testing set (11 abnormal, 14 normal). Hepatic lesions were physician annotated using a modified PERCIST threshold, and boundary definition by gradient edge detection. The 2D U-Net was trained independently five times for 100,000 iterations using a linear combination of binary cross-entropy and dice losses with a stochastic gradient descent algorithm. Performance metrics included: positive predictive value (PPV), sensitivity, F1 score and area under the precision–recall curve (PR-AUC). Five different pixel area thresholds were used to filter noisy predictions.ResultsA total of 233 lesions were annotated with each abnormal study containing a mean of 4 ± 2.75 lesions. A pixel filter of 20 produced the highest mean PPV 0.94 ± 0.01. A pixel filter of 5 produced the highest mean sensitivity 0.74 ± 0.02. The highest mean F1 score 0.79 ± 0.01 was produced with a 20 pixel filter. The highest mean PR-AUC 0.73 ± 0.03 was produced with a 15 pixel filter.ConclusionDeep neural networks can automatically detect hepatic lesions in 68Ga-DOTATATE PET. Ongoing improvements in data annotation methods, increasing sample sizes and training methods are anticipated to further improve detection performance.

Highlights

  • Gastroenteropancreatic neuroendocrine tumors most commonly metastasize to the liver; high normal background 68Ga-DOTATATE activity and high image noise make metastatic lesions difficult to detect

  • 68Ga-DOTATATE PET/CT has demonstrated the highest accuracy in detection and staging of gastroenteropancreatic neuroendocrine tumors (GEP-Neuroendocrine tumors (NETs)) [5]), and high uptake is essential for effective 177Lu-DOTATATE peptide receptor radionuclide therapy [6]

  • 58 of the studies met the inclusion criteria of fewer than 10 welldefined, non-confluent lesions without liver disease that would significantly impact the interpretation of the study or result in poorly defined or abnormal background activity. These studies were paired with 68 68Ga-DOTATATE PET/CT studies evaluating for metastatic NETs which were found to have no liver metastases

Read more

Summary

Introduction

Gastroenteropancreatic neuroendocrine tumors most commonly metastasize to the liver; high normal background 68Ga-DOTATATE activity and high image noise make metastatic lesions difficult to detect. Despite the treatment benefit of 177Lu-DOTATATE of improved progression-free survival, only 17% had a partial response and only 1% had a complete response. The majority of these patients had persistent disease, potentially requiring retreatment [7]. Subjective 68Ga-DOTATATE PET/CT interpretation is relatively consistent [10], an objective method could greatly improve the assessment of therapy response and facilitate the development of next-generation therapies

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.